Status:

COMPLETED

Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborating Sponsors:

Genzyme, a Sanofi Company

Conditions:

Acute Myeloid Leukemia

Myelodysplastic Syndrome

Eligibility:

All Genders

60+ years

Phase:

PHASE2

Brief Summary

The goal of this clinical research study is to study how effective treatments with clofarabine alone and clofarabine given in combination with ara-C are in the treatment of leukemia and high-risk myel...

Detailed Description

Clofarabine is a chemotherapy drug that is designed to interfere with the growth and development of cancer cells. Ara-C is a chemotherapy drug which is approved for the treatment of AML and MDS. Altho...

Eligibility Criteria

Inclusion

  • Previously untreated AML and high-risk MDS ( \> 10% blasts, or International Prognostic Scoring System (IPSS) intermediate-2). Prior therapy with hydroxyurea, single agent chemotherapy (e.g. decitabine), hematopoietic growth factors, biological or "targeted" therapies are allowed.
  • Age \> 60 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status \</= 2.
  • Sign a written informed consent form.
  • Adequate liver function (total bilirubin \< 2mg/dL,serum glutamic pyruvic transaminase (SGPT) or Serum glutamic oxaloacetic transaminase (SGOT) \< x 4 upper limit of normal (ULN)) and renal function (serum creatinine \< 2mg/dL).

Exclusion

  • Patients with \>= New York Heart Association (NYHA) grade 3 heart disease as assessed by history and/or physical examination.

Key Trial Info

Start Date :

July 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2008

Estimated Enrollment :

95 Patients enrolled

Trial Details

Trial ID

NCT00088218

Start Date

July 1 2004

End Date

February 1 2008

Last Update

August 7 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

M.D. Anderson Cancer Center

Houston, Texas, United States, 77030

Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). | DecenTrialz